These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32199681)

  • 1. Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43.
    Bai Y; Yang Y; Tang Y
    Eur Urol; 2020 Jun; 77(6):e158. PubMed ID: 32199681
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Yunjin Bai, Yubo Yang, Yin Tang's Letter to the Editor, re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01, Study. Eur Urol 2020;77:636-43.
    Bandini M; Necchi A
    Eur Urol; 2020 Jun; 77(6):e159-e160. PubMed ID: 32184002
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer?
    Vila-Reyes H; DeCastro GJ; McKiernan JM
    Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF
    Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Vila-Reyes H; Joel DeCastro G; McKiernan JM
    Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
    Necchi A; Bandini M; Calareso G; Raggi D; Pederzoli F; Farè E; Colecchia M; Marandino L; Bianchi M; Gallina A; Colombo R; Fossati N; Gandaglia G; Capitanio U; Dehò F; Giannatempo P; Lucianò R; Salonia A; Madison R; Ali SM; Chung JH; Ross JS; Briganti A; Montorsi F; De Cobelli F; Messina A
    Eur Urol; 2020 May; 77(5):636-643. PubMed ID: 31882281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6.
    Li R; Jain RK; Sexton WJ
    Eur Urol; 2021 Oct; 80(4):e99. PubMed ID: 34364728
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
    Hussain SA; Porta N; Hall E; Qureshi M; Lewis R; Huddart R; James ND
    Eur Urol; 2021 Aug; 80(2):e51-e52. PubMed ID: 34053780
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6.
    Yang Y; Wei X; Han P
    Eur Urol; 2019 Aug; 76(2):e33. PubMed ID: 31054785
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Sanjay B. Kulkarni, Pankaj M. Joshi, Marco Bandini, et al.'s Letter to the Editor re: Sanad Saad, Nadir I. Osman, Christopher R. Chapple. Female Urethra: Is Ventral the True Dorsal? Eur Urol 2020;78:e218-9.
    Saad S; Osman NI; Chapple CR
    Eur Urol; 2022 Jan; 81(1):e16-e17. PubMed ID: 34740503
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307-15.
    Sundar S; Symonds P
    Eur Urol; 2021 Aug; 80(2):e49-e50. PubMed ID: 34024651
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306.
    Panebianco V; Barentsz J; Narumi Y; Catto J;
    Eur Urol; 2018 Nov; 74(5):e109. PubMed ID: 30029821
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6.
    Li R; Spiess PE; Gilbert SM; Necchi A
    Eur Urol; 2019 Aug; 76(2):e34. PubMed ID: 31056228
    [No Abstract]   [Full Text] [Related]  

  • 14. The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer.
    Bandini M; Calareso G; Raggi D; Marandino L; Colecchia M; Gallina A; Giannatempo P; Pederzoli F; Gandaglia G; Fossati N; Capitanio U; Colombo R; Salonia A; Briganti A; Montorsi F; De Cobelli F; Messina A; Necchi A
    Eur Urol Oncol; 2021 Oct; 4(5):829-833. PubMed ID: 32605888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14.
    Quan C; Chen J; Hu J
    Eur Urol; 2023 Apr; 83(4):e109-e110. PubMed ID: 36702694
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Chao Quan, Jinbo Chen, and Jiao Hu's Letter to the Editor re: Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer: 3-Year Median Follow-up Update of PURE-01 Trial. Clin Cancer Res 2022;28:5107-14.
    Basile G; Bandini M; Montorsi F; Necchi A
    Eur Urol; 2023 Apr; 83(4):e111-e112. PubMed ID: 36707359
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder Cancer.
    Vetterlein MW; Gild P; Fisch M; Rink M
    Eur Urol; 2020 Aug; 78(2):e77-e78. PubMed ID: 32376138
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9.
    Soria F; D'Andrea D; Gontero P; Shariat SF
    Eur Urol Focus; 2022 Mar; 8(2):633-634. PubMed ID: 33875390
    [No Abstract]   [Full Text] [Related]  

  • 19. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
    Garg M; Goel A; Prakash J
    Eur Urol; 2013 Jan; 63(1):e6. PubMed ID: 23021089
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.